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Abstract
Introduction—Vitamin D may have an immunological role in Crohn’s disease (CD) and
ulcerative colitis (UC). Retrospective studies suggested a weak association between vitamin D
status and disease activity but have significant limitations.
Methods—Using a multi-institution inflammatory bowel disease (IBD) cohort, we identified all
CD and UC patients who had at least one measured plasma 25-hydroxy vitamin D [25(OH)D].
Plasma 25(OH)D was considered sufficient at levels ≥ 30ng/mL. Logistic regression models
adjusting for potential confounders were used to identify impact of measured plasma 25(OH)D on
subsequent risk of IBD-related surgery or hospitalization. In a subset of patients where multiple
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measures of 25(OH)D were available, we examined impact of normalization of vitamin D status
on study outcomes.
Results—Our study included 3,217 patients (55% CD, mean age 49 yrs). The median lowest
plasma 25(OH)D was 26ng/ml (IQR 17–35ng/ml). In CD, on multivariable analysis, plasma
25(OH)D < 20ng/ml was associated with an increased risk of surgery (OR 1.76 (1.24 – 2.51) and
IBD-related hospitalization (OR 2.07, 95% CI 1.59 – 2.68) compared to those with 25(OH)D ≥
30ng/ml. Similar estimates were also seen for UC. Furthermore, CD patients who had initial levels
< 30ng/ml but subsequently normalized their 25(OH)D had a reduced likelihood of surgery (OR
0.56, 95% CI 0.32 – 0.98) compared to those who remained deficient.
Conclusion—Low plasma 25(OH)D is associated with increased risk of surgery and
hospitalizations in both CD and UC and normalization of 25(OH)D status is associated with a
reduction in the risk of CD-related surgery.
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INTRODUCTION
Crohn’s disease (CD) and ulcerative colitis (UC) are chronic immunologically mediated
diseases that often have their onset at a young age and are associated with recurrent episodes
of relapsing disease activity1. Nearly two-thirds of patients with CD and one-fifth of those
with UC will eventually require surgery for management of their refractory disease or
disease-related complication2–6. A larger proportion of patients will require at least one
IBD-related hospitalization2. Thus, both surgery and hospitalization represent major events
in the natural history of inflammatory bowel diseases (IBD; CD and UC) and are responsible
for a substantial portion of the estimated $6 billion in annual healthcare costs associated
with these diseases7. Identification of risk factors for such adverse outcomes and
interventions that may reduce the risk of such adverse outcomes are an important need.
Vitamin D has been classically described in association with its effect on bone
mineralization. However, there is considerable interest in the immunological effects of
vitamin D8–14. Indeed, a recent body of literature has substantiated a significant role of
vitamin D in IBD. Residence in areas with reduced ultraviolet light exposure15 or a lower
predicted plasma vitamin D level16 is associated with an increased risk for CD. Furthermore,
retrospective or cross-sectional studies have suggested an association between lower vitamin
D and disease activity in CD17–19. However, they have been limited by the inability to
temporally separate the effect of plasma 25(OH)D, the best measure of an individuals
vitamin D status, and subsequent adverse outcomes. Consequently, there is a need for
prospective studies examining the association between vitamin D status and risk for
subsequent surgery or hospitalization. In addition, it is also of interest to examine if a change
in vitamin D status, in particular, normalization of plasma 25(OH)D levels, can attenuate the
risk associated with deficient vitamin D. This hypothesis is supported by laboratory data
from animal models where vitamin D supplementation ameliorated colitis20, and from a
randomized controlled trial where CD patients in remission randomized to vitamin D had a
lower rate of relapse over 12 months compared to placebo21.
We performed the present study with the aims of (1) examining the association between
plasma 25(OH)D and risk of subsequent IBD-related surgery or hosptalization in a large
cohort of CD and UC patients; and (2) analyzing whether normalization of vitamin D status
in those with insufficient or deficient levels is associated with a reduction in risk for surgery
or hospital stays.
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METHODS
Study Population
The data source for our study was an electronic medical record (EMR) based cohort of CD
and UC patients from two tertiary medical centers in Boston serving a population of over 4
million patients in the Greater Boston area as well as neighboring states. The development
and validation of our cohort has been described in detail in previous publications22. From
among patients with at least one International Classification of Diseases, 9th edition (ICD-9-
CM) clinical modification code for CD (555.x) or UC (556.x) (n = 24,182), we refined our
cohort by developing an algorithm incorporating codified data as well as narrative free text
concepts from the EMR identified using natural language processing tools. The positive
predictive value of our final algorithms were 97% for both CD and UC, confirmed in an
independent validation cohort, and yielded a final CD cohort of 5,506 patients and 5,522 UC
patients.
Development of the study cohort
This study was restricted to a subset of 3,217 CD or UC patients with at least one measured
plasma 25(OH)D level. Patients who had ≥ 1 plasma 25(OH)D measure were similar in age
to those without a vitamin D level, but were more likely to be female (61% vs. 50%), use
immunomodulator or anti-TNF therapy, and undergo an IBD-related surgery (16% vs. 10%)
or hospitalization (40% vs. 27%). The plasma 25(OH)D was measured as part of routine
clinical care at the two hospitals using high performance liquid chromatography with mass
spectrometry since 2008 and radioimmunoassay prior to that with similar normal values
across both assays. The dates of plasma 25(OH)D measurements, the lowest, and highest
values were retrieved and modeled as normal (> 30ng/ml), insufficient (20 – 29.9ng/ml) or
deficient (< 20ng/ml) according to current recommendations23–25.
Variables and Outcomes
Information on current age, age at first ICD-9-CM code for CD or UC, gender, race (white
or non-white) and non-IBD co-morbidity modeled using the Deyo modification of the
Charlson co-morbidity index26 were obtained as was duration of follow-up within our
healthcare system. Using the electronic prescription function of our EMR, we ascertained
use of IBD-related medications including aminosalicylates, systemic corticosteroids,
immunomodulators (azathioprine, 6-mercaptopurine, methotrexate), and anti-tumor necrosis
factor α monoclonal antibodies (anti-TNF). We also additionally assessed for use of
prescription vitamin D supplementation as well as use of high dose ergocalciferol (50,000
international units (IU) weekly).
Our primary outcomes were undergoing an IBD-related surgery or hospitalization identified
using the appropriate procedure ICD-9 codes for surgical procedures (Supplemental Table 1)
or the presence of CD or UC as the primary diagnosis for hospitalizations. Patients were
censored at the first such event and plasma 25(OH)D measures beyond this time point were
excluded from the analysis.
Statistical Analysis
Data was analyzed using Stata 11.1 (StataCorp, College Station, TX). Continuous variables
were summarized using means and standard deviations while categorical variables were
expressed as percentages. The t-test was used to compare continuous variables with the chi-
square test being used for comparison of categorical variables. Univariate logistic regression
was used to identify predictors of IBD-related surgery, constructing separate models for CD
and UC and modeling plasma 25(OH)D status using the lowest measured level (prior to
surgery or end of follow-up) and the three strata described above. Multivariable logistic
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regression was then used to examine the independent effect of vitamin D status on risk of
IBD-related surgery or hospitalization. A two-sided p-value < 0.05 indicated statistical
significance.
For the analysis of the effect of normalization of vitamin D status, we restricted the cohort to
patients with at least 2 measures of plasma 25(OH)D examining whether they had ever
achieved a normal level of plasma 25(OH)D prior to the event of interest (surgery or
hospitalization). Similar multivariable regression models were constructed to examine both
predictors of normalization of plasma 25(OH)D as well as to examine the effect of such
normalization on risk of surgery and hospitalization. Ethical approval for our study was
obtained from the Institutional Review Board of Partners Healthcare.
RESULTS
Study Population
Our study included a total of 3,217 patients (55% CD, 45% UC) with at least one measured
plasma 25(OH) D. The mean age of the cohort was 49 years with a mean age of 41 years at
the first ICD-9 code for CD or UC (Table 1). Most of the patients were Caucasian (81%)
and a majority were female (61%). At least half the patients had a history of systemic
corticosteroid use (54%) while just under a quarter had a history of anti-TNF use (21%). The
median lowest plasma 25(OH)D was 26 ng/ml (interquartile range (IQR) 17 – 35ng/ml) with
median highest plasma 25(OH)D of 35ng/ml (IQR 26 – 44 ng/ml). Just under a third of
patients each had insufficient (28%) or deficient (32%) 25(OH)D levels. The median
number of 25(OH)D measurements prior to surgery or end of follow up was 1 (IQR 1–3);
half the cohort (49%) had 2 or more measurements.
Plasma 25(OH)D and risk of IBD-related surgery and hospitalization
Table 2 describes the association between the lowest measured plasma 25(OH)D and
subsequent risk of surgery. Only 10% of CD patients who were never deficient in vitamin D
subsequently underwent an IBD-related surgery compared to 13% of those with insufficient
levels (Odds ratio (OR) 1.70, 95% confidence interval (CI) 1.24 – 2.34) and 17% of those
with deficient levels below 20ng/ml (OR 2.05, 95% CI 1.53 – 2.75). The association
between plasma 25(OH)D and surgery remained significant on multivariable analysis
adjusting for age, gender, Charlson co-morbidity, season of measurement, duration of follow
up and use of immunomodulator or anti-TNF therapies. A similar association was seen for
CD-related hospitalizations with a dose-response effect observed for progressively lower
levels of 25(OH)D (Table 2).
For patients with UC, an association between plasma 25(OH)D below 20ng/ml and elevated
risk of surgery and hospitalization was observed with an effect size similar to that observed
for CD. However, the stratum with insufficient vitamin D (levels between 20–29.9ng/ml)
did not demonstrate a statistically significant elevation in risk of surgery or hospitalization
(Table 2).
Predictors of Normalization of Vitamin D status
We examined predictors of normalization of vitamin D status in patients with at least 2
measurements of plasma 25(OH)D (median interval between the two measures was 294
days). Just over three-quarters of patients with CD (404/538, 75%) and UC (80%) had a
normal plasma 25(OH)D ≥ 30ng/ml following an initial measure below this threshold
(“normalized” patients). Table 3 describes the variables associated with normalization.
Older age increased likelihood of normalization (OR 1.16 for every 10 year increase in age,
95% CI 1.06 – 1.28) as did a higher baseline vitamin D level (OR 1.12, 95% CI 1.09 – 1.15
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for every 1ng/ml). Supplemental vitamin D use was seen in 52% of those with low vitamin
D levels and was associated with a higher likelihood of normalization (OR 1.87, 95% CI
1.31 – 2.66). Non-white race was associated with a significant lower likelihood of
normalization (OR 0.53, 95% CI 0.30 – 0.92).
Effect of normalization of vitamin D status on risk of surgery and hospitalization
We then examined if normalization of vitamin D status influenced risk of surgery and
hospitalization in CD and UC. In patients with CD, those who had an initial low level of
25(OH)D but subsequently normalized their values had a significantly lower likelihood of
requiring surgery on multivariable analysis (OR 0.56, 95% CI 0.32 – 0.98) compared to
those who remained low (Table 4, Figure 1). While this difference was also seen for
hospitalizations on univariate analysis, the effect did not achieve independent statistical
significance on multivariable analysis. In contrast, we did not observe a reduction in the
likelihood of surgery or hospitalization associated with normalization of vitamin D status in
UC patients. CD patients who normalized their vitamin D status also had a significantly
lower median C-reactive protein (10.7mg/dl vs. 16.2 mg/dl, adjusted regression co-efficient
(β): −5.2, 95% CI −9.5 to −1.02) that those who remained low; this effect was not seen in
UC (β: −8.5mg/dl, 95% CI −35.2 to 18.2 mg/dl).
We repeated the analysis including all patients with at least one measure of vitamin D status,
carrying forward the single plasma 25(OH)D measure for those with only one lab value. The
association between normalization of plasma 25(OH)D and reduced risk of surgery in CD
remained (OR 0.48, 95% CI 0.32 – 0.70) with a significant effect also observed for reduced
risk of hospitalization (OR 0.52, 95% CI 0.38 – 0.69). No effect was observed for ulcerative
colitis.
DISCUSSION
Vitamin D plays an important immunologic role in inflammatory bowel diseases9–13. In a
large IBD cohort, we demonstrate that (1) low plasma 25(OH)D is an independent risk
factor for both UC and CD-related surgery and hospitalization; and (2) CD patients who
normalize their vitamin D status have a lower risk of subsequent CD-related surgery that
those whose levels remained low.
There has been growing data on vitamin D status in cohorts of IBD patients. However, many
of the studies have limitations that preclude drawing conclusions regarding the immunologic
effect of vitamin D. First, a majority of studies focused on describing a cross-sectional
prevalence of insufficient or deficient vitamin D in their cohorts, or risk factors thereof, with
a limited ability to prospectively examine consequences of vitamin D deficiency17–19, 27.
Second, the studies that did examine the association with disease activity were limited by
retrospective ascertainment of cumulative disease burden such that the low vitamin D could
have temporally followed the outcome measured17–19. In this study, using a large cohort of
over 3,200 IBD patients with at least one measured plasma 25(OH)D, we demonstrate that
low plasma 25(OH)D is independently associated with an increased risk of subsequent
surgery and hospitalization in both CD and UC patients. Furthermore, in CD, we also
observed a dose-response effect with a progressively higher frequency of surgery and
hospitalizations in those with insufficient (25(OH)D between 20–29.9ng/ml) and deficient
(25(OH)D < 20ng/ml) levels.
Though one cannot exclude the possibility that improvement in vitamin D status was
consequent to increasing physical activity and outdoor sun exposure as better control of
disease is achieved, considerable evidence both from our study and prior work suggests this
is unlikely to be the explanation for our findings. First, in our study, the effect of
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normalization of plasma 25(OH)D on reduction in risk of CD-related surgery remained
significant after adjusting for inflammatory burden quantified using median C-reactive
protein levels, as well as use of medical therapies (immunomodulator or anti-TNF) initiated
to achieve disease control, suggesting that vitamin D status is not merely a marker of disease
activity or severity but potentially a biologically relevant parameter. Furthermore, there is
also supporting biologic evidence on how vitamin D could influence disease activity in CD.
In an IL-10 knockout model of colitis, Cantorna et al. demonstrated that administration of
1,25-dihydroxy cholecalciferol was associated with amelioration of colitis with a dose-
response effect similar to that observed in our study20. In a second study, a vitamin D
analogue similarly ameliorated TNBS mediated colitis and decreased both clinical and
macroscopic activity scores28. In addition, Zhu et al. demonstrated that administration of
vitamin D was associated with a reduction in the colonic expression of TNF-related genes29.
A randomized controlled trial examined the effect of vitamin D supplementation on disease
activity in CD. Jorgensen et al. randomized 94 patients to placebo or vitamin D 1200 IU
daily in conjunction with 1200mg/day of calcium in both arms21. At the end of one year,
there was a trend towards lower frequency of relapse in the vitamin D (13%) compared to
the placebo arm (29%, p=0.06). The median plasma 25(OH)D increased from 27ng/ml to
38ng/ml at 3 months and was sustained at the higher level through 12 months. Our findings
of the effect of normalization similarly support that attainment of a vitamin D level above
30ng/ml is associated with a reduction in risk of CD-related surgery. In our study, though
reduction in CD-related hospitalizations was not statistically significant on multivariable
analysis, we did find a statistically significant drop in rate of hospitalizations of a similar
magnitude when the cohort was expanded to include those with at least one measured
plasma 25(OH)D, suggesting consistency in effects. In a smaller study, Miheller et al.
compared two different vitamin D formulations – cholecalciferol 1000 IU/day and
alfacalcidol 0.50mcg/day and found a reduction in the Crohn’s disease activity index
(CDAI), C-reactive protein and SIBDQ30. Our findings support this and expand it to a larger
cohort by additionally demonstrating that CD patients who normalized their plasma
25(OH)D measurements had a lower median C-reactive protein than those who remained
low.
It was interesting that we observed this effect of normalization among CD but not UC
patients. First, this may indicate that a higher plasma 25(OH)D threshold is required to attain
immunologic activity in UC compared to CD. The lack of an effect of insufficient (plasma
25(OH)D 20–29.9mg/dl) vitamin D on risk of surgery or hospitalization in UC supports this
plausibility. However, there is also biological evidence suggesting a stronger interplay
between vitamin D status and CD compared to UC. In a previous study, Ananthakrishnan et
al. found that lower predicted plasma 25(OH)D was associated with an increased risk for
incident CD but not UC16. Similarly, Ulitsky et al. identified an association between low
vitamin D and disease activity in CD but not UC17. Using chromatin immunoprecipitation
and parallel DNA sequencing (ChIP-Seq), Ramagopalan et al. found that calcitriol
administration led to enrichment of vitamin D receptor (VDR) binding sites in proximity to
several autoimmune loci including the nucleotide-binding oligomerization domain
containing 2 locus (NOD2) on chromosome 1631. NOD2 is a risk allele with a strong effect
on CD but not UC, and is associated with ileal disease location, fibrostenosing phenotype,
and need for surgery32. Also mediated through VDR, administration of calcitriol leads to
induction of NF-κB inhibitory proteins, and reduction in NF-κB mediated production of
TNF and other inflammatory cytokines33. Binding of VDR by 1,25(OH)D regulates NOD2
transcription and induces NF-κB -mediated expression of defensins (DEFB2/HBD2)34.
Our findings have a few clinical implications. To our knowledge, ours is the largest cohort
examining the effect of vitamin D status on natural history and outcomes of CD and UC.
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Furthermore, prior studies have been limited by cross-sectional assessment of vitamin D
status at a single time point, or cumulative average of vitamin D measures over the entire
study period17–19. Using our distinct and repeated measures of plasma 25(OH)D, we were
able to additionally demonstrate that CD patients who normalized their vitamin D had a
lower likelihood of surgery. This finding, in conjunction with the supportive laboratory
data10, 20 and the Jorgensen trial21 suggest a need for prospective studies of vitamin D as an
intervention in the management of IBD. Further data is also needed on whether the role of
vitamin D is restricted to maintenance of remission as examined in the trial, or if it could
also play a role in induction in combination with existing therapy.
There are a few limitations to our study. First, plasma 25(OH)D levels were not available for
all patients in our cohort; there likely exists both a provider- and a patient-level bias in
obtaining vitamin D levels. However, patients for whom measures of vitamin D status was
available were sicker than those without a measured level suggesting that our findings are
particularly relevant in a cohort enriched for adverse outcomes. Second, not all patients had
multiple measures of plasma vitamin D, and at pre-defined time points. However, our
findings remained robust in analyses that included those with single or multiple measures.
Third, we did not have information on dietary vitamin D or supplemental vitamin D that was
not captured in the electronic medical records. However, since our primary variable, directly
measured plasma 25(OH)D, is a comprehensive reflection of dietary intake, vitamin D
absorption, and vitamin D from other sources including sun exposure, we believe our
findings to have greater biological relevance than studies examining vitamin D intake alone.
As in most observational studies, the effect of unmeasured confounders cannot be excluded.
We also did not have the ability to adjust in detail for disease location which could predict
need for surgery. However, for small bowel disease location to be a confounder, it would
have to be associated with both our predictor (vitamin D) and outcome (surgery), and
several prior studies have failed to identify an association between small bowel CD with low
vitamin D status17–19. Furthermore, vitamin D intake contributes to only a small fraction on
an individual’s overall vitamin D status35. Finally, it is also possible that vitamin D repletion
is a marker of compliance with treatment, or overall health status. Causality cannot be
inferred from an observational study, but the wealth of laboratory data supporting a
bioactive role of vitamin D in intestinal inflammation provides significant biologic
plausibility to this association.
In conclusion, we demonstrate that low plasma 25(OH)D is associated with increased risk of
surgery in CD and UC, with a dose-response relationship observed in CD. Furthermore, CD
patients who normalized their vitamin D had a lower risk of subsequent surgery than those
who remained deficient suggesting a need to examine the role of vitamin D supplementation
as an intervention in the management of CD. However, only a subset of patients had
measured 25(OH)D at multiple time points, and detailed dietary vitamin D intake, physical
activity, or sunlight exposure was not available. Larger prospective studies in other cohorts
as well as randomized intervention trials are required to definitively establish if modulating
vitamin D status can help in the therapy of IBD and improve patient outcomes.
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Figure 1.
Normalization of plasma 25(OH)D and risk of surgery in Crohn’s disease and ulcerative
colitis
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Table 1
Characteristics of the study cohort
Characteristic Number (%)
Total 3,217 (100%)
Median age (in years) (IQR) 48 (34 – 63)
Median age at first IBD ICD-9 code (in years) (IQR) 40 (28 – 54)
Female 1,954 (61%)
Race
      White 2,812 (87%)
      Non-white 238 (8%)
      Other/Unknown 167 (5%)
Mean Charlson score (SD) 3.7 (3.6)
IBD type
      Crohn’s disease 1,763 (55%)
      Ulcerative colitis 1,454 (45%)
IBD-related medications
      Corticosteroids 1,732 (54%)
      5-aminosalicylates 1,942 (60%)
      Immunomodulators 1,255 (39%)
      Anti-TNF biologics 688 (21%)
IBD-related surgery 525 (16%)
IBD-related hospitalization 1,293 (40%)
Median lowest plasma 25(OH)D measurement (IQR) 26 ng/mL (17 – 35)
Median highest plasma 25(OH)D measurement (IQR) 35 ng/mL (26 – 44)
IBD – inflammatory bowel diseases, IQR – interquartile range, SD – standard deviation, TNF – tumor necrosis factor
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Table 3
Multivariate Analysis of Predictors of Normalization of plasma 25(OH)D in patients with Crohn’s disease and
ulcerative colitis
Predictor Odds Ratio 95% confidence interval
Age (for every 10 years) 1.16 1.06 – 1.28
Non-white race 0.53 0.30 – 0.92
Lowest vitamin D level (for every 1 ng/ml increase) 1.12 1.09 – 1.15
Supplemental Vitamin D use 1.87 1.31 – 2.66
Season of initial measurement
      Spring Reference
      Summer 1.29 0.78 – 2.15
      Fall 1.16 0.75 – 1.82
      Winter 1.49 0.99 – 2.26
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Table 4
Effect of normalization of plasma 25(OH)D and risk of surgery and hospitalizations in Crohn’s disease and
ulcerative colitis
Surgery Hospitalizations
Did not normalize Normalize Did not normalize Normalized
Crohn’s disease
Unadjusted 1.0 0.51 (0.32 – 0.82) 1.0 0.64 (0.44 – 0.96)
Adjusted† 1.0 0.56 (0.32 – 0.98) 1.0 0.78 (0.51 – 1.25)
Ulcerative colitis
Unadjusted 1.0 1.02 (0.45 – 2.31) 1.0 0.88 (0.52 – 1.47)
Adjusted† 1.0 0.75 (0.29 – 1.93) 1.0 0.78 (0.44 – 1.40)
†Adjusted for age, gender, race, Charlson co-morbidity, use of immunomodulators or anti-TNF biologics, and duration of follow-up
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